Menon Biosensors demonstrates pathogen detection capabilities

Menon Biosensors, Inc., a molecular biochemistry company, announced on Friday that its molecular mirroring nuclear magnetic resonance technology successfully demonstrated pathogen quantification at concentrations as low as one colony forming unit per sample.

The company's M2 NMR technology was able to detect pathogens at concentrations ranging from one CFU to 100 million CFU per sample, demonstrating eight orders of magnitude in dynamic range. The technology was able to detect pathogens like Clostridium difficile, Mycobacterium tuberculosis, Bacillus anthracis and Yersinia pestis in less than one hour.

"Using the unique platform detection technology of M2, our scientists were able to develop a novel amplification approach, combined with random sample access to achieve quantification of eight orders of magnitude in dynamic range," Suresh Menon, the president of Menon Biosensors, said. "This method is applicable to quantify both bacteria and viruses while delivering unmatched sensitivity."

Menon said the company would continue to demonstrate the wide dynamic range of the technology for hepatitis C, HIV and pathogens able to infect immunocompromised hosts.

"This dynamic range and sensitivity has applications in food safety, biodefense and livestock screening, where timely detection and quantification are often very useful," Menon said.

Since 2005, Menon Biosensors has developed and tested 35 bacterial and virus assays. The M2 technology was initially developed to provide rapid countermeasures against bioterrorism.